# UroGen Pharma Ltd. (URGN) FY2026 Q2 P&L / Income Statement

- Company: UroGen Pharma Ltd. (URGN)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001437749-26-025794
- Page: https://plicit.ai/financials/urgn/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/urgn-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 72,456,000 US dollars
- **Cost of revenue**: 6,572,000 US dollars
- **Gross profit**: 65,884,000 US dollars
- **Operating expenses (calculated)**: 65,773,000 US dollars
- **Operating income (loss)**: 111,000 US dollars
- **Other income (expense), net (calculated)**: negative 8,833,000 US dollars
- **Loss before income taxes**: negative 8,722,000 US dollars
- **Income tax expense**: 5,629,000 US dollars
- **Net loss**: negative 14,351,000 US dollars
- **Jelmyto**: 22,028,000 US dollars
- **Zusduri**: 50,429,000 US dollars
- **Selling, general and administrative expenses**: 48,437,000 US dollars
- **Research and development expenses**: 17,336,000 US dollars
- **Revenue before reconciliation (calculated)**: 72,457,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- **Components above reported revenue (calculated)**: negative 1,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.